
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Mayo Clinic College of Medicine, Rochester, Minnesota and 2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Requests for reprints: Celine M. Vachon, Mayo Clinic College of Medicine, Charlton 6-239, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-9977; Fax: 507-266-2478. E-mail: vachon.celine{at}mayo.edu
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Mammographic breast density may reflect exposure to hormones and growth factors that stimulate cell division in breast stroma and epithelium (3, 5, 6). This hypothesis is supported by the consistent observation of changes in mammographic density in response to menopausal hormones (7-9), tamoxifen (10-12), and the correlation with serum insulin-like growth factor-I among premenopausal women (5, 13, 14). Additionally, direct studies of mammographically dense tissues suggest that density may represent increased epithelial cellular concentration (15, 16), growth factors (insulin-like growth factor-I; refs. 16, 17), stromal fibrosis, and epithelial hyperplasia (18).
If mammographic density reflects a greater cellular concentration or increased proliferation in either the stroma or epithelium, then areas of increased density may be more susceptible to the initiation and promotion of breast cancers than areas of lower densities. Ursin et al. (19) reported recently that ductal carcinoma in situ lesions occurred in mammographically dense regions in a small series of patients. If mammographic density exerts its influence on the microenvironment, one might expect invasive tumors to also arise in the densest regions of the breast. It would also follow that there would be a stronger association of breast density and risk on the side that eventually develops the cancer relative to the contralateral. We address these questions in the context of a well-designed matched case-control study using prediagnostic screening mammograms available on average 7 years before the clinical diagnosis of cancer.
| Materials and Methods |
|---|
|
|
|---|
Two controls with no prior history of breast cancer from the screening practice were matched to each case on age (within 5 years), final screening exam date (4 months), menopausal status at final exam date (pre or post), time between baseline and final mammogram (8 months), number of prior screening mammograms (one mammogram), and residence (same county). Some controls were ineligible due to unavailability of mammograms or previous breast cancer identified on medical record abstraction. Weight, height, and hormone replacement therapy (HRT) were abstracted from the Mayo Clinic medical record for all serial mammogram dates, including the earliest and latest mammograms used in these analyses. Weight and height are routinely measured and recorded at medical exams associated with the mammogram. HRT was abstracted from patient reported medication use in the medical record over the entire mammogram period.
Height and weight were used to construct body mass index (BMI) in kilograms per meters squared. All remaining patient information was obtained from a clinical database of self-reported information gathered at each visit.
Location of the tumor was abstracted from radiology and pathology reports when available and classified into one of four quadrants (superior-lateral, superior-medial, inferior-lateral, and inferior-medial); if location was not specified on the reports, the original mammogram at time of diagnosis was obtained and the study radiologist (K.R.B.) classified the location based on the diagnostic four-view mammogram. Women with multiple tumors in different quadrants (n = 9) were excluded from regional density analyses.
Prediagnostic mammograms were available on all cases and controls. The earliest mammogram during the preceding 10-year period, but at least 2 years before breast cancer or corresponding exam date, was used for primary analyses. These mammograms ranged from 2.1 to 10.4 years before the cancer (or the corresponding exam date for controls), with a mean ± SD of 7.0 ± 1.5 years. The earliest mammogram was >5 years before cancer, or index date, for >90% of the participants. We also performed analyses using the mammogram closest to 3 years before the breast cancer (3.0 ± 1.0 years) to determine whether our findings were similar as you get closer to the date of diagnosis.
For both the earliest mammogram and those on average 3 years before the breast cancer, weight was available within 1 week for 85% of participants, whereas height was available for 68% to 70%. For the remainder, weight and height were used from the closest abstracted date; the median interval was 17 and 22 months for weight and 25 and 27 months for height for the 3-year and earliest mammograms, respectively. HRT information was available over the entire mammogram interval (and consequently at the two mammogram dates evaluated) for 84% of participants; for 16%, this was unknown.
This study was approved by the Mayo Clinic Institutional Review Board.
Breast Density Estimation
Mammograms were digitized on a Lumiscan 75 scanner with 12-bit grayscale depth. The pixel size was 0.130 x 0.130 mm2 for both the 18 x 24 cm2 and 24 x 30 cm2 films. All four views [left and right mediolateral oblique (MLO) and left and right craniocaudal (CC)] were digitized. Batch files were created composed of both cases and controls with randomly assigned views, dates, and sides within a woman to maximize precision of estimates (20). A 5% repeat set of images was included within each batch file for assessment of reliability. Percentage breast density (dense area divided by total area x 100) and absolute dense area (cm2) were estimated for each view using a computer-assisted thresholding program that has routinely been used in studies of breast density (1, 2, 21, 22). Briefly, two thresholds are set by a trained programmer; one separates the breast from the background and the second separates dense from nondense tissue (see Fig. 1
). In the batch files examined for this study, we consistently showed high reliability (r > 0.93) while reading over 500 duplicate images across varying time frames.
|
|
Statistical Analyses
Summaries of the distributions of demographic and other variables are presented as means and SDs or counts and percentages. The baseline risk factors considered were BMI, menopausal status, family history of breast cancer, age at first birth, number of births, and HRT use.
Conditional logistic regression was used to calculate odds ratios (OR) with adjustment for potential confounding factors. Breast density measures were categorized based on quartiles of the control distributions and on modified categories previously published by Boyd et al. (22) for purposes of comparison (modified because we had very few women above 75% density). Associations were examined by laterality: ipsilateral or contralateral to the cancer (with the corresponding side used for controls) and by CC and MLO views. The C-statistic, or the area under the receiver operating characteristic curve from unconditional logistic regression models, was used to summarize the strength of the case-control prediction for the various models. C-statistics reflect how often a model correctly identifies the case in a random case-control pair as having higher risk and range from of 0.5 (random chance) to 1.0 (perfect prediction). Differences in associations between breast density and breast cancer corresponding to different mammogram sides within a person were assessed using logistic regression models with Generalized Estimating Equations correcting for within-subject correlations (23-25).
To examine the association of regional density and breast cancer, we first performed a case-only analysis, describing the distributions of percentage density in the four regions as well as the location of greatest density by location of the eventual tumor. We next modeled the association of regional density with breast cancer using conditional logistic regression. We could not examine the proportion of density in the region of the eventual cancer with risk because it was highly correlated with overall percentage density (r = 0.9). To isolate the effects due to regional density from overall density, we subtracted regional percentage density from overall percentage density; negative values of this difference would indicate that regional density is larger in the area of the eventual cancer relative to the overall breast. This calculation was essentially equivalent to extracting the smallest principal component. To reduce any potential residual confounding, we also included overall percentage density in all models. Analyses were conducted within view (CC versus MLO) on the mammograms used for the primary analyses above. In addition, to explore whether 7 years is too early to detect an association between regional density and breast cancer, we examined mammograms taken closer to the time of diagnosis (on average 3 years before breast cancer or corresponding exam date). Similar to the above, the association of regional percentage density and breast cancer was examined adjusting for overall percentage density.
Analyses were also conducted among all breast cancers combined and for invasive breast cancers only.
| Results |
|---|
|
|
|---|
20 years]. BMI was inversely associated with percentage density [35.5% (SD, 14.9), 27.8% (SD, 12.5), 23.9% (SD, 13.2), and 19.6% (SD, 12.6) for BMI <23.5, 23.5-26.1, 26.1-29.9, and 29.9+]. The associations of these risk factors with dense area were similar in direction, except BMI, which showed a positive association with dense area as seen in other studies to date (data not shown; ref. 29).
|
|
The next set of analyses was designed to determine whether the region of the breast with the greatest proportion of dense tissue was the one where the tumor was most likely to develop. The CC view and the MLO view were evaluated separately. Among the 363 cases available for these analyses (9 cases had multiple tumors in more than one region), the greatest proportion of density was in the CC-L (versus CC-M) and the MLO-I (versus MLO-S) regions. However, there was no clear association between region with highest density and location of the tumor (Table 3 ).
|
|
| Discussion |
|---|
|
|
|---|
We attempted to address the question of whether breast density in the location of the eventual tumor enhanced risk prediction using two approaches. We first examined breast density from the ipsilateral versus contralateral mammograms with risk. Although the mammographic appearances of both breasts are relatively symmetric, the mammographic densities are not identical (27, 30). Our results showed that breast density predicted breast cancer similarly for the two sides. These findings are consistent with the only study known that assessed breast density from both mammogram sides in relation to risk (26). We next focused on the region of the breast where the cancer eventually developed. There was no association of percentage density in the region of the cancer with subsequent risk while correcting for the overall measure of percentage density in the breast. This correction enabled us to look at the contribution of density that was independent of overall percentage density and assured that the originally observed association between overall percentage density and risk was retained. Hypothesizing that 7 years might be too early in the disease process, we examined mammograms 3 years before diagnosis, but the results were unchanged.
These findings provide provocative evidence for overall breast density as a general predisposing marker for future breast cancer and not specifically in the breast with the cancer or at the location of the greatest density. Two other well-established markers for invasive breast cancer, including benign breast disease and lobular carcinoma in situ, also seem to confer a general susceptibility of risk to both breasts. A recent publication from the largest cohort of benign breast disease to date (n = 9,087) with a median 15-year follow-up showed that 45% of incident breast cancers occurred in the contralateral breast to the benign biopsy (31). Similarly, lobular carcinoma in situ is considered a strong risk marker of future breast cancer in both breasts (32, 33), and there is recent evidence that ductal carcinoma in situ may also be associated with ipsilateral (OR, 1.9) and contralateral (OR, 2.0) breast cancer (34).
Breast density is associated with several established risk factors for breast cancer, including positive associations with HRT, nulliparity, late age at first birth, alcohol intake, and inverse associations with age, postmenopausal status, and BMI (26, 30, 35-40). These risk factors account for only 20% to 30% of variation in breast density (26, 28, 29) and there is evidence that genetics and their interaction with environment likely account for the remaining variation (37, 41). Genes for breast density may predispose women to high densities in both breasts, translating to increased breast cancer risk.
In addition, mammographic density has been hypothesized to parallel age-related involution in the breast, which involves the reduction in size and number of acini per lobule as well as the replacement of the extralobular stroma by fat (42-45). Both mammographic density and involution are influenced by reproductive factors and change with age, with the greatest changes after menopause. Recent data from a large benign breast disease cohort study (31) suggest that involution as assessed on biopsy specimen is associated with breast cancer risk reduction (46). Involution status at the site of the benign biopsy was associated with a reduction of both ipsilateral and contralateral events. Thus, one could speculate that breast densities mirror involution of the breast and both represent a general marker of breast cancer risk.
Our negative findings of an association between cancer-region densities with subsequent breast cancer risk are in apparent contrast with the only other published study that has examined density in the location of the cancer. Ursin et al. (19) examined a small series of ductal carcinoma in situ patients and found 21 of 22 ductal carcinoma in situ examined occurred in dense areas of the breast and 61% of these lesions also occurred in the upper-outer quadrant, which also corresponded to the highest density. Although the reason for the discrepant results is not immediately obvious, it may relate in part to differences in timing of the mammograms evaluated (which were at the time or immediately preceding the cancer in the Ursin study versus either an average of 3 or 7 years in ours), the focus: invasive versus in situ lesions, or the inclusion of a control group. Unlike the study by Ursin et al. (19), our study was able to compare the cancer-region density with that in the corresponding region of controls.
Both studies, however, suffer from several limitations, including the use of a crude four-quadrant approach for examining locations of percentage density and using a two-dimensional film to address volume. The use of magnetic resonance imaging or other imaging modalities may provide more precision to the location of the densities (and the tumor) than film mammography. In addition, densities can be diffuse or focal in nature, and an overall estimate of regional percentage density would not capture the distribution of densities in the region that may be important to the development of breast cancer. The capability to coregister the exact location of the tumor on serial mammograms would greatly improve the precision with which this question could be answered.
Prior studies have suggested that the association of breast density with subsequent breast cancer may in part be due to bias wherein increased density masks subsequently detected breast cancer (47). Because we did not see an association between cancer-region density and subsequent risk, this would imply that other areas in the breast are also prone to developing breast cancer. As such, we provide suggestive evidence that masking bias is not responsible for the breast density and breast cancer association. If masking bias was at play, we would also have expected a stronger association with regional density closer to diagnosis.
Our case-control study had several strengths, including the close matching on pertinent factors, high participation rates due to the retrospective design, mammograms from at least 5 years before breast cancer for >90% of cases and controls, medical recordabstracted weight, height, and risk factor data on all cases and controls generally at time of mammogram, and importantly, the quantitative assessment of density. Further, this is the first study to examine the location of density with breast cancer risk and comprehensively examine density in the breast that becomes cancerous. Limitations include the minimal ethnic diversity of this Midwest population and the clinic-based design. Although this was not a population-based study, by restricting to the 120-mile radius and requiring serial mammograms on all women, the study population was closer to a community-based population rather than a referral or high-risk population.
In conclusion, percentage density and dense area are both measures of breast density that are strongly associated with breast cancer risk. The association is not limited to mammograms from the ipsilateral breast or to the regions that develop the breast cancer. We therefore conclude that density is a marker of risk for both breasts and continued research to understand the biology of breast density is warranted.
| Acknowledgments |
|---|
| Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 8/31/06; revised 10/11/06; accepted 10/17/06.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Ghosh, K. R. Brandt, T. A. Sellers, C. Reynolds, C. G. Scott, S. D. Maloney, M. J. Carston, V. S. Pankratz, and C. M. Vachon Association of Mammographic Density with the Pathology of Subsequent Breast Cancer among Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 872 - 879. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Tice, S. R. Cummings, R. Smith-Bindman, L. Ichikawa, W. E. Barlow, and K. Kerlikowske Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model Ann Intern Med, March 4, 2008; 148(5): 337 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, T. A. Sellers, E. E. Carlson, J. M. Cunningham, C. A. Hilker, R. L. Smalley, D. J. Schaid, L. E. Kelemen, F. J. Couch, and V. S. Pankratz Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer Cancer Res., September 1, 2007; 67(17): 8412 - 8418. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Vachon, V. S. Pankratz, C. G. Scott, S. D. Maloney, K. Ghosh, K. R. Brandt, T. Milanese, M. J. Carston, and T. A. Sellers Longitudinal Trends in Mammographic Percent Density and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 921 - 928. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |